Update on low malignant potential ovarian tumors.
Low malignant potential (LMP) ovarian tumors represent a small subset of epithelial ovarian cancers that were first identified 70 years ago but were recognized in a systematic way only within the last 30 years. These lesions afflict women at a much younger age than invasive ovarian cancer, behave in a more indolent manner, and have a much more favorable prognosis. The management of women with LMP tumors is primarily surgical; adjuvant therapy plays little role in early disease and its use in advanced disease is not well defined. Ongoing investigations are attempting to define prognostic factors that may assist clinicians in the appropriate application of postoperative therapy.
Menzin
A W
AW
Department of Obstetrics and Gynecology, North Shore University Hospital, North Shore-Long Island, Jewish Health System, Manhasset, New York, USA.
D014408:Biomarkers, Tumor / Q000032:analysis; D018394:CA-125 Antigen / Q000032:analysis; D018282:Cystadenocarcinoma, Mucinous / Q000453:epidemiology / Q000473:pathology / Q000601:surgery*; D018283:Cystadenocarcinoma, Papillary / Q000453:epidemiology / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D015994:Incidence; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000601:surgery*; D011379:Prognosis; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen